Healthcare & Insurance
Disclosure of received notifications
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 July 2020 Disclosure of received notifications Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received notifications of Norges Bank.
Monday, July 06, 2020
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and continued safety of linzagolix at week 52 Results confirm linzagolix as a potential best-in-class
Monday, July 06, 2020
Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study
Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study Paris, 6 July 2020 – 7.00 a.m. CET - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX) (“Pixium
Monday, July 06, 2020
Idorsia announces positive results in the second Phase 3 study of daridorexant
Results confirm and reinforce the efficacy and safety profile from the first pivotal studyCompany targets filing the New Drug Application (NDA) around the end of 2020Idorsia to host an investor webcast to discuss the second Phase 3 results today at 14:00hrs CEST Allschwil, Switzerland – July
Monday, July 06, 2020
Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., July 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase
Friday, July 03, 2020
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 3, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Société Générale S.A. has informed us that, as of July 1, 2020, Société
Friday, July 03, 2020
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies
COPENHAGEN, Denmark, July 3, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The
Friday, July 03, 2020
Ageas and BlackRock: Transparency notification
Ageas and BlackRock: Transparency notification In accordance with the rules on financial transparency*, BlackRock has notified Ageas on 2 July 2020 that, on 1 July 2020, its interest has exceeded the legal threshold of 5% of the shares issued by Ageas. Its current shareholding stands at 5.09%.
Friday, July 03, 2020
ECMOHO Announces First Quarter 2020 Unaudited Financial Results
SHANGHAI, China, July 03, 2020 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the non-medical health and wellness market in China, today announced its unaudited financial results for the first quarter ended March
Friday, July 03, 2020
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Orphazyme A/SCompany announcement No. 39/2020
Friday, July 03, 2020
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 3, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Société Générale S.A. has informed us that, as of June 29, 2020, Société
Friday, July 03, 2020
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESHRE Virtual 36th Annual Meeting,
Friday, July 03, 2020
Aurora Spine Announces New Chief Financial Officer
CARLSBAD, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSX VENTURE:ASG) announced the promotion of Chad Clouse to the position of Chief Financial Officer (CFO), effective July 2, 2020. Mr. Clouse graduated from Pennsylvania State
Friday, July 03, 2020
CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, July 02, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, Thursday, July 2nd, by Protara Therapeutics, Inc. (Nasdaq: TARA), please note that in the first paragraph, the amount of shares of common stock should be 25,700, not 3,700. The corrected
Thursday, July 02, 2020
Avricore Health Announces Shares for Debt Transaction
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce that it has entered into shares for debt agreements, to satisfy an aggregate of $126,949 of the Company’s outstanding debts. The Company has
Thursday, July 02, 2020
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company
Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related to the company’s support of certain independent charitable co-pay foundations from 2010 to 2014As
Thursday, July 02, 2020
Braingrid Limited Provides Update On COVID-19 and Announces Request for Extension to File Interim Financial Statements and Management's Discussion
TORONTO, July 02, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) (“Braingrid”) wishes to provide an update on the COVID-19 pandemic as it affects Braingrid and the status of the filing of its interim financial statements and accompanying management's discussion and analysis, and
Thursday, July 02, 2020
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of stock
Thursday, July 02, 2020
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients PARIS and TARRYTOWN, N.Y. - July 2, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19
Thursday, July 02, 2020
miRagen Regains Compliance With Nasdaq Listing Requirements
BOULDER, Colo., July 02, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing
Thursday, July 02, 2020
